Showing results (131-140 of 166) with videos related to

Sort By:
Pageof 17
Scientific Reports|May 31, 2022
Congenital sideroblastic anemia model due to ALAS2 mutation is susceptible to ferroptosisKoya Ono, Tohru Fujiwara, Kei Saito, et al.
Blood Advances|May 20, 2026
Atezolizumab for relapsed/refractory extranodal NK/T-cell lymphoma: the phase II NCCH1903/ATTACK trialShinichi Makita, Junji Koya, Yasuhiro Suzuki, et al.
International Journal of Clinical Oncology|May 28, 2025
Efficacy and safety of epcoritamab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma: 3-year follow-up from the EPCORE NHL-3 trialKoji Izutsu, Takahiro Kumode, Junichiro Yuda, et al.
Cancer Science|November 3, 2023
Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B-cell lymphomaKoji Izutsu, Takahiro Kumode, Junichiro Yuda, et al.
Blood Advances|June 30, 2020
Nationwide survey of systemic chronic active EBV infection in Japan in accordance with the new WHO classificationIchiro Yonese, Chizuko Sakashita, Ken-Ichi Imadome, et al.
International Journal of Hematology|June 14, 2022
Efficacy and safety of modified BLd therapy for Japanese patients with transplant-ineligible multiple myelomaSatsuki Murakami, Masaki Ri, Masato Ito, et al.
Cancer Science|April 1, 2021
Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphomaHidetsugu Kawai, Kiyoshi Ando, Dai Maruyama, et al.
Haematologica|September 14, 2014
Prognostic significance of pleural or pericardial effusion and the implication of optimal treatment in primary mediastinal large B-cell lymphoma: a multicenter retrospective study in JapanTomohiro Aoki, Koji Izutsu, Ritsuro Suzuki, et al.
Cancer Science|May 4, 2021
A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphomaYasuhito Terui, Shinya Rai, Koji Izutsu, et al.
Blood Advances|January 20, 2023
Darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: results of an Asian phase 2 studyWon-Seog Kim, Noriko Fukuhara, Dok-Hyun Yoon, et al.
Pageof 17